This outcome carries substantial clinical relevance, given the close association between reduced adipose tissue mass and improvements in insulin sensitivity and dyslipidemia, both of which are paramount in addressing obesity-related comorbidities. The gene discussed is INS; the disease is metabolic syndrome.